jmro

A Case Report of EGFR-mutated Metastatic Lung Adenocarcinoma with Long-term Survival on Systemic Treatment

Author(s) :

Daniel Dulf1,2, Paul Kubelak1,2,  Dana Iancu1, Tudor Eliade Ciuleanu1,2

1 “Ion Chiricuță” Institute of Oncology, Cluj-Napoca, Romania

2  UMF “Iuliu Hațieganu” Cluj-Napoca, Romania

Corresponding author: Tudor-Eliade Ciuleanu, Email: tudor_ciuleanu@hotmail.com


Published: Journal of Medical and Radiation Oncology 1 (2021) 51-58, , , - DOI: 10.53011/JMRO.2021.01.05

Open Access

Full text
Cite
×

Cite

Daniel Dulf1,2, Paul Kubelak1,2,  Dana Iancu1, Tudor Eliade Ciuleanu1,2

.

A Case Report of EGFR-mutated Metastatic Lung Adenocarcinoma with Long-term Survival on Systemic Treatment. Journal of Medical and Radiation Oncology 1 (2021) 51-58. DOI:10.53011/JMRO.2021.01.05
March 22, 2021 0 Comments

Abstract

Metastatic non-small cell lung cancer has historically been associated with a poor prognosis. The introduction of targeted agents against certain molecules involved in cellular pathways has shown improved responses, but long-term survivors are still rare.

We present the case of a patient with lung adenocarcinoma harboring sensitizing EGFR mutations who showed an impressive survival of more than 9 years following a combination of systemic therapies consisting of cytotoxic drugs and EGFR TKIs that were very well tolerated.

Key Words

EGFR, EGFR-TKIs, Erlotinib, Non-small Cell Lung Cancer, Osimertinib, Targeted Therapy, TKI,
Fig. 1. CT scan (Baseline) – 3cm consolidation process in the right lung with multiple infiltrations, bilateral micronodules, moderate right pleural effusion
Fig. 2. CT SCAN (Baseline) -Osteolityc lesion – D4 vertebral body
Fig. 3. Selected CT scans while the patient was receiving Erlotinib (November 2010 – August 2015)
Fig. 4. Selected CT scans between August 2015 and February 2019 while the patient was receiving Osimertinib

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments